Archive: Company News

Company News: MediGene Obtains Additional US Patent Protection for EndoTAG-1

September 16, 2010 – MediGene AG (Frankfurt: MDG, Prime Standard) has obtained a patent on the manufacturing process for the drug candidate EndoTAG(TM)-1 from the US patent office. Patent no. 7,794,747 protects the manufacturing process used for EndoTAG-1 as well as the product manufactured by this process. The term of the patent “Method of producing a cationic liposomal preparation comprising a lipophilic compound” will end on January 25, 2024.

More information after the jump

Company News: Okairos Raises €16 Million in Series B Financing

Swiss-Italian vaccine play Okairos today announced the closing of a €16 million series B financing round. The proceeds will be used to further advance Okairos’ product portfolio. The vaccines developed by Okairos are based on new, potent adenovirus vectors that can engage the cellular arms of the immune system to elicit a strong immune response involving T cells. The company is addressing major infectious diseases, e.g. malaria, HIV, hepatitis C and universal influenza. The financing was led by Versant Ventures and joined by the Boehringer Ingelheim Venture Fund. All existing investors – BioMedPartners, LSP and Novartis Venture Funds – also participated in the round. For further information, please visit the company’s website.

Company News: Probiodrug Appoints Kumar Srinivasan as Chief Business Officer

Probiodrug (Halle, Germany) has appointed Dr Kumar Srinivasan, previously Vice President, Global Business Development at Wyeth, to Chief Business Officer. Wyeth was acquired by Pfizer in 2009. Probiodrug has a focus on neurodegenerative diseases, in particular Alzheimer’s disease. In this indication, the company pursues a novel target and pathway and is preparing for the start of clinical development of one of its lead candidates, a small molecule inhibitor of the enzyme glutaminyl cyclase (QC). Kumar Srinivasan, MBA, has a background as research chemist and is an experienced pharma / biotech dealmaker. He will be responsible for Probiodrug’s global business development activities and will be based in Philadelphia, PA. The full press release can be found here.

Company News: MediGene Sells Full European Rights for Eligard® to Astellas for EUR 25 Million and Ongoing Royalties

MediGene AG (Frankfurt, Prime Standard, MDG, TecDAX) has announced the sale of full European marketing and distribution rights to Eligard® (leuprolide acetate, for the treatment of hormone-dependent prostate cancer) to Astellas Pharma Europe Ltd. (London, “Astellas”), previously MediGene’s European marketing partner for Eligard®. Astellas will make one-off payments totalling EUR 25 million, while MediGene remains entitled to royalties. There will be no further costs to MediGene. The sales price reflects the full NPV of all future Eligard® revenues while allowing MediGene to benefit from continued Eligard® growth. For more information, please see the full press release.


1 156 157 158 163